TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39527236

Group type: EXPERIMENTAL
Intervention: Upper Extremity Robotic Rehabilitation (RR) - ExoRehab X, Houston Bionics, twice/week for 6 weeks alongside conventional treatment.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR) - 5 days/week for 6 weeks.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (CR and RR)
Number of subjects: 34
Study: 39527466

Group type: EXPERIMENTAL
Intervention: Darolutamide plus ADT and docetaxel
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo plus ADT and docetaxel
Number of subjects: 148
Study: 39527516

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention over 4 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 90
Study: 39527532

Group type: EXPERIMENTAL
Intervention: ACTIVE (online exercise intervention)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CON (waitlist control)
Number of subjects: 32
Study: 39527705

Group type: EXPERIMENTAL
Intervention: Digital platform for recurrent UTI management
Number of subjects: 31
Study: 39527960

Group type: EXPERIMENTAL
Intervention: Betibeglogene autotemcel (beti-cel) gene therapy
Number of subjects: 18
Study: 39527970

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1039
Study: 39528049

Group type: EXPERIMENTAL
Intervention: First Subsequent Therapy (FST) with platinum-based chemotherapy and PARP inhibitor
Number of subjects: 806
Study: 39528058

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg plus EGb 761 160 mg daily
Number of subjects: 500

Group type: COMPARATOR
Intervention: Aspirin 100 mg and clopidogrel 75 mg daily
Number of subjects: 500
Study: 39528108

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 806
Study: 39528111

Group type: EXPERIMENTAL
Intervention: Solriamfetol (75 mg/d for 3 days, then 150 mg/d for 2 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 39528324

Group type: EXPERIMENTAL
Intervention: Tenofovir amibufenamide therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39528323

Group type: EXPERIMENTAL
Intervention: Tenofovir amibufenamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39528478

Group type: EXPERIMENTAL
Intervention: lenalidomide-bortezomib-dexamethasone (RVd) induction for ≥3 cycles
Number of subjects: 633
Study: 39528489

Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) 20-mg/kg administered weekly in cycle 1, then biweekly
Number of subjects: 21
Study: 39528665

Group type: EXPERIMENTAL
Intervention: AUTO4 (TRBC1-directed autologous chimeric antigen receptor T cells)
Number of subjects: 10
Study: 39528780

Group type: EXPERIMENTAL
Intervention: Community exercise programmes
Number of subjects: 64
Study: 39528916

Group type: EXPERIMENTAL
Intervention: 3-week multimodal prehabilitation program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual clinical care (control group)
Number of subjects: 112
Study: 39528951

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 44
Study: 39528997

Group type: EXPERIMENTAL
Intervention: Individually tailored exercise and nutrition program for six months
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Nutrition program adherence measured by MEDAS
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Malnutrition risk assessed by NRS2002
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 182
Study: 39529032

Group type: EXPERIMENTAL
Intervention: Nurse-led aftercare programme (pre-discharge support and proactive follow-up support over 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study: 39529054

Group type: EXPERIMENTAL
Intervention: 3 mg of CAF/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 6 mg of CAF/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 9 mg of CAF/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 39529061

Group type: EXPERIMENTAL
Intervention: FSI-ECD + VP
Number of subjects: 160

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 160
Study: 39529079

Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 294
Study: 39529089

Group type: EXPERIMENTAL
Intervention: Adapted facilitation of the Mothers and Babies intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implementation as usual (standard education)
Number of subjects: 0
Study: 39529139

Group type: EXPERIMENTAL
Intervention: Placement intervention in intervention stores
Number of subjects: 0
Study: 39529169

Group type: EXPERIMENTAL
Intervention: Iparomlimab (200 mg or 3 mg/kg for patients with body weight < 40 kg, IV, Q3W) until disease progression, intolerable toxicities, withdrawal of consent, death, or up to 2 years.
Number of subjects: 120
Study: 39529175

Group type: EXPERIMENTAL
Intervention: Sobriety Treatment and Recovery Teams (START)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Collaboration strategies (e.g., staff co-location, communication quality)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Absence of third-party resource support
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Absence of communication quality
Number of subjects: 17
Study: 39529188

Group type: EXPERIMENTAL
Intervention: Lethal means counseling (LMC) plus 2 cable-style gun locks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lethal means counseling (LMC)
Number of subjects: 200
Study: 39529199

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex (LDLPFC) once daily for 10 consecutive workdays, with parameters of 120% resting motor threshold, 50 Hz bursts repeated at 5 Hz, 600 pulses per session (total duration 3 min 9 s)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 0
Study: 39529317

Group type: EXPERIMENTAL
Intervention: Acar's uterine compressive atony sutures
Number of subjects: 22
Study: 39529482

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg over 10 min, followed by 0.4 μg/kg/h continuous infusion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 45
Study: 39529711

Group type: EXPERIMENTAL
Intervention: mHealth intervention (Step Away) for reduced drinking
Number of subjects: 0
Study: 39529939

Group type: EXPERIMENTAL
Intervention: High-dose multistrain probiotic mix (Sinquanon)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 39530130

Group type: EXPERIMENTAL
Intervention: SHR4640
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39530262

Group type: EXPERIMENTAL
Intervention: Complete resection of HFO area
Number of subjects: 160

Group type: COMPARATOR
Intervention: Not completely resected HFO area
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Complete HFO area resection
Number of subjects: 160

Group type: COMPARATOR
Intervention: Resected volume as predictor
Number of subjects: 160
Study: 39530465

Group type: EXPERIMENTAL
Intervention: Personalized nutrition and exercise intervention (high-protein diet with daily protein supplementation, functional training with strength and aerobic exercises)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study: 39530472

Group type: EXPERIMENTAL
Intervention: Promoting Optimal Physical Exercise for Life (PROPEL) program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Group cardiorespiratory exercise (GCE) alone
Number of subjects: 57
Study: 39530534

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 39530558

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg intravenously every 4 weeks up to 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 30
Study: 39530574

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin 1.25 mg/kg (Days 1, 8, and 15)
Number of subjects: 40
Study: 39530624

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil plus XB2001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trifluridine/tipiracil
Number of subjects: 0
Study: 39530627

Group type: EXPERIMENTAL
Intervention: 10 mg tarlatamab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg tarlatamab
Number of subjects: 0
Study: 39531039

Group type: EXPERIMENTAL
Intervention: GDM group (n=22)
Number of subjects: 37

Group type: COMPARATOR
Intervention: non-GDM group (n=15)
Number of subjects: 37
Study: 39531116

Group type: EXPERIMENTAL
Intervention: CAYA intervention (nurse-led HIV prevention)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 450
Study: 39531161

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator (placebo or active comparator)
Number of subjects: 0
Study: 39531233

Group type: EXPERIMENTAL
Intervention: Culturally tailored video
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Generic video
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Gift card incentive
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Monetary incentives (adjusted for trust)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (ink pen incentive)
Number of subjects: 125
Study: 39531231

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both BCBT and PCT
Number of subjects: 96
Study: 39531274

Group type: EXPERIMENTAL
Intervention: Thrive clinical pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39531369

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25μg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Dual therapy (FF/VI 100/25μg or UMEC/VI 62.5/25μg)
Number of subjects: 10355
Study: 39531391

Group type: EXPERIMENTAL
Intervention: Safety in Dementia (SiD) decision aid
Number of subjects: 500

Group type: COMPARATOR
Intervention: Web-based information control
Number of subjects: 500
Study: 39531423

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg every 6 weeks
Number of subjects: 101
Study: 39531433

Group type: EXPERIMENTAL
Intervention: Remote social conversations with research staff over 20-minute video or telephone calls three times per week for 4 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Passive control condition for 4 weeks
Number of subjects: 196
Study: 39531687

Group type: EXPERIMENTAL
Intervention: Mindfulness (measured by FFMQ-15)
Number of subjects: 0
Study: 39531689

Group type: EXPERIMENTAL
Intervention: Balovaptan
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 39531903

Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 118
Study: 39531997

Group type: EXPERIMENTAL
Intervention: Unblinded continuous vital sign monitoring with nursing alerts
Number of subjects: 250

Group type: COMPARATOR
Intervention: Blinded continuous vital sign monitoring
Number of subjects: 250
Study: 39532185

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GemCis)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Capecitabine (CAP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ctDNA positivity before ACT
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ctDNA on-ACT at 12 weeks from C1D1
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ctDNA on-ACT at 24 weeks from C1D1
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ctDNA anytime post-surgery
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients
Number of subjects: 101
Study: 39532238

Group type: EXPERIMENTAL
Intervention: Education + automated digital reminders + individualized feedback
Number of subjects: 268

Group type: COMPARATOR
Intervention: Education + automated digital reminders
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Two telehealth problem-solving sessions with an interventionist
Number of subjects: 268
Study: 39532313

Group type: EXPERIMENTAL
Intervention: Healthcare providers' identification of hazards in the home setting for adolescents with brain injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hazard Priority Matrix Activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thematic analysis of hazards
Number of subjects: 0
Study: 39532348

Group type: EXPERIMENTAL
Intervention: Individualised transfusion strategy (prescription of RBCT restricted to patients with Hb ≤9.0 g/dL and oxygen extraction ratio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention group (restrictive approach)
Number of subjects: 0
Study: 39532350

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39532363

Group type: EXPERIMENTAL
Intervention: Social robot as cotherapist during 9 weekly sessions (B)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline without the robot during 4 weekly sessions (A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Follow-up without the robot during 4 weekly sessions (C)
Number of subjects: 8
Study: 39532375

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 453

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 453
Study: 39532780

Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 39532835

Group type: EXPERIMENTAL
Intervention: Entinostat 5 mg orally once weekly for 14-day lead-in, followed by entinostat and nivolumab (PD1 inhibitor)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Entinostat and nivolumab
Number of subjects: 27
Study: 39532861

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neutralizing antibody titer
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Anti-Spike binding antibody concentration
Number of subjects: 42
Study: 39532934

Group type: COMPARATOR
Intervention: ICF core set for post-acute musculoskeletal conditions (Polish sample)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ICF core set for post-acute musculoskeletal conditions (Spanish sample)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ICF components 'Body Functions' and 'Environmental Factors'
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ICF entity 'b280 Sensation of pain'
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ICF entity 'e225 Climate'
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: ICF entity 'd430 Lifting and carrying objects'
Number of subjects: 840

Group type: COMPARATOR
Intervention: ICF entity 'd450 Walking'
Number of subjects: 840
Study: 39533001

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control (standard of care alone or with hydroxychloroquine)
Number of subjects: 185
Study: 39533015

Group type: EXPERIMENTAL
Intervention: Plerixafor (n=24, 39.3%)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Non-plerixafor-based regimens (n=37, 60.7%)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Salvage auto-HCT (PM patients)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for PM patients
Number of subjects: 877
Study: 39533115

Group type: EXPERIMENTAL
Intervention: Vicadrostat (10 mg)
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11000
Study: 39533185

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 9881

Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (AWS)
Number of subjects: 9881

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 9881
Study: 39533186

Group type: EXPERIMENTAL
Intervention: Ciprofol (N=40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Propofol (N=38)
Number of subjects: 78
Study: 39533194

Group type: EXPERIMENTAL
Intervention: Ciprofol combined with alfentanil
Number of subjects: 217

Group type: COMPARATOR
Intervention: Propofol combined with alfentanil
Number of subjects: 217
Study: 39533204

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF on day 7 after chemotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: PEG-rhG-CSF on day 3 after chemotherapy
Number of subjects: 160
Study: 39533248

Group type: EXPERIMENTAL
Intervention: Antenatal education sessions
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no antenatal education)
Number of subjects: 140
Study: 39533250

Group type: EXPERIMENTAL
Intervention: AI-cTB plus systematic biopsy (SB)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Routine cTB plus SB
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: AI-cTB
Number of subjects: 380

Group type: COMPARATOR
Intervention: cTB
Number of subjects: 380
Study: 39533260

Group type: EXPERIMENTAL
Intervention: eSyM, an electronic health record-integrated, ePRO-based symptom management program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall SIMPRO strategies
Number of subjects: 0
Study: 39533271

Group type: EXPERIMENTAL
Intervention: Crisis Response Plan
Number of subjects: 82

Group type: COMPARATOR
Intervention: Self-guided Safety Planning
Number of subjects: 82
Study: 39533310

Group type: EXPERIMENTAL
Intervention: Digital foot examinations using a Clinical Decision Support System
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional foot examinations
Number of subjects: 100
Study: 39533330

Group type: EXPERIMENTAL
Intervention: Closed-loop automatic control of the inspiratory fraction of oxygen (FiO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 39533349

Group type: EXPERIMENTAL
Intervention: Continuous upadacitinib
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo to upadacitinib
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Both groups (continuous upadacitinib and placebo to upadacitinib)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 420
Study: 39533363

Group type: EXPERIMENTAL
Intervention: Potentiation warm-up protocol with jumps combined with sprints with change of direction
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual warm-up program
Number of subjects: 17
Study: 39533408

Group type: EXPERIMENTAL
Intervention: EAA + omega-3 fatty acids
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study: 39533412

Group type: EXPERIMENTAL
Intervention: ePROMs monitoring
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 260
Study: 39533414

Group type: EXPERIMENTAL
Intervention: 45-min nap during simulated night shift work
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-nap condition during simulated night shift work
Number of subjects: 10
Study: 39533424

Group type: EXPERIMENTAL
Intervention: Integration of traditional care with modern healthcare systems
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group (no integration of traditional care)
Number of subjects: 510
Study: 39533437

Group type: EXPERIMENTAL
Intervention: Adaptive strategies for timely treatment adoption
Number of subjects: 0
Study: 39534099

Group type: EXPERIMENTAL
Intervention: Livmoniplimab monotherapy (3mg to 1500mg Q2W)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Livmoniplimab in combination with budigalimab (500mg Q4W)
Number of subjects: 57
Study: 39534205

Group type: EXPERIMENTAL
Intervention: Kidney BEAM physical activity digital health intervention (DHI)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 340
Study: 39534248

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) session embedded in physical education or physical activity lessons, 6 to 10 minutes, five days a week for 12 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 8
Study: 39534354

Group type: EXPERIMENTAL
Intervention: QFR-guided CABG (n=69)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CAG-guided CABG (n=119)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: QFR-guided CABG
Number of subjects: 188

Group type: COMPARATOR
Intervention: CAG-guided CABG
Number of subjects: 188
Study: 39534390

Group type: EXPERIMENTAL
Intervention: PEMF therapy plus eccentric exercise
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham group (eccentric exercise only)
Number of subjects: 65
Study: 39534453

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 39534481

Group type: EXPERIMENTAL
Intervention: bimekizumab 160 mg every 4 weeks
Number of subjects: 0
Study: 39534593

Group type: EXPERIMENTAL
Intervention: Carrageenan- and sorbitol-containing nasal spray (CS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline solution (SS)
Number of subjects: 41
Study: 39534856

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (baseline systemic inflammation)
Number of subjects: 0
Study: 39534972

Group type: EXPERIMENTAL
Intervention: Brexpiprazole 2 or 3 mg/day
Number of subjects: 259
Study: 39535306

Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 504

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 504